We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana Gains on Strong Membership Base and Sound Cash Reserves
Read MoreHide Full Article
Humana Inc. (HUM - Free Report) remains well-poised for growth on the back of improved premium revenues, an aging U.S. population, acquisitions and adequate cash generation abilities. A strong 2025 outlook reinforces the growth prospects of the stock.
Let’s delve deeper and analyze the factors aiding Humana.
HUM’s Impressive Earnings Surprise History
Humana boasts a robust earnings surprise record. It has outpaced estimates in each of the trailing four quarters, the average surprise being 15.35%.
Humana’s Solid 2025 Outlook
The health insurer exhibits a robust business outlook for 2025. Revenues are anticipated to be in the band of $126-$128 billion, the mid-point of which indicates an improvement of 7.8% from the 2024 figure.
The Insurance segment’s revenues are estimated to be within $121-$123 billion. Revenues of the CenterWell segment are forecasted in the band of $20.5-$21.5 billion.
Adjusted earnings per share are estimated to be around $16.25. The mid-point of the outlook indicates growth of 0.2% from the 2024 figure.
HUM’s Continued Top-Line Growth
Humana experiences revenue growth, primarily fueled by increased premiums tied to a solid customer base in its Medicaid and Medicare operations. During 2024, premium revenues rose 10.7% year over year. Through its Insurance segment, Humana provides cost-effective health plans and is steadily expanding its footprint across various U.S. regions. These offerings have contributed to multiple contract wins and renewals from both federal and state agencies.
The growing elderly population in the United States is expected to drive sustained demand for Humana’s Medicare plans. To further support senior care nationwide, the company has its CenterWell brand, introduced in 2022.
Other health insurers offering Medicaid and Medicare plans throughout the United States include Centene Corporation (CNC - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Molina Healthcare, Inc. (MOH - Free Report) .
Humana’s Inorganic Growth Initiatives
Humana has pursued strategic acquisitions to enhance capabilities and its nationwide footprint. Key buyouts include Family Physicians Group, Curo, Enclara, iCare and Inclusa. The acquisition of Enclara enhanced its hospice pharmacy services, while the iCare deal in Wisconsin expanded its Medicare footprint. Additionally, acquiring all assets of Wisconsin-based Inclusa further bolstered its capabilities in care coordination. HUM also takes a disciplined approach to portfolio optimization by divesting non-core operations to enhance profitability.
HUM’s Sound Financial Position
Humana boasts sufficient cash reserves and adequate cash generation abilities. It held cash, cash equivalents and investment securities totaling $20.4 billion as of Dec. 31, 2024, comfortably exceeding its long-term debt of $11.1 billion. Sound operating cash flows have enabled HUM to adopt a disciplined capital deployment strategy through share repurchases and dividend payments. GAAP cash flow from operations is anticipated to be between $2.4 billion and $2.9 billion for 2025.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humana Gains on Strong Membership Base and Sound Cash Reserves
Humana Inc. (HUM - Free Report) remains well-poised for growth on the back of improved premium revenues, an aging U.S. population, acquisitions and adequate cash generation abilities. A strong 2025 outlook reinforces the growth prospects of the stock.
Let’s delve deeper and analyze the factors aiding Humana.
HUM’s Impressive Earnings Surprise History
Humana boasts a robust earnings surprise record. It has outpaced estimates in each of the trailing four quarters, the average surprise being 15.35%.
Humana’s Solid 2025 Outlook
The health insurer exhibits a robust business outlook for 2025. Revenues are anticipated to be in the band of $126-$128 billion, the mid-point of which indicates an improvement of 7.8% from the 2024 figure.
The Insurance segment’s revenues are estimated to be within $121-$123 billion. Revenues of the CenterWell segment are forecasted in the band of $20.5-$21.5 billion.
Adjusted earnings per share are estimated to be around $16.25. The mid-point of the outlook indicates growth of 0.2% from the 2024 figure.
HUM’s Continued Top-Line Growth
Humana experiences revenue growth, primarily fueled by increased premiums tied to a solid customer base in its Medicaid and Medicare operations. During 2024, premium revenues rose 10.7% year over year. Through its Insurance segment, Humana provides cost-effective health plans and is steadily expanding its footprint across various U.S. regions. These offerings have contributed to multiple contract wins and renewals from both federal and state agencies.
The growing elderly population in the United States is expected to drive sustained demand for Humana’s Medicare plans. To further support senior care nationwide, the company has its CenterWell brand, introduced in 2022.
Other health insurers offering Medicaid and Medicare plans throughout the United States include Centene Corporation (CNC - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and Molina Healthcare, Inc. (MOH - Free Report) .
Humana’s Inorganic Growth Initiatives
Humana has pursued strategic acquisitions to enhance capabilities and its nationwide footprint. Key buyouts include Family Physicians Group, Curo, Enclara, iCare and Inclusa. The acquisition of Enclara enhanced its hospice pharmacy services, while the iCare deal in Wisconsin expanded its Medicare footprint. Additionally, acquiring all assets of Wisconsin-based Inclusa further bolstered its capabilities in care coordination. HUM also takes a disciplined approach to portfolio optimization by divesting non-core operations to enhance profitability.
HUM’s Sound Financial Position
Humana boasts sufficient cash reserves and adequate cash generation abilities. It held cash, cash equivalents and investment securities totaling $20.4 billion as of Dec. 31, 2024, comfortably exceeding its long-term debt of $11.1 billion. Sound operating cash flows have enabled HUM to adopt a disciplined capital deployment strategy through share repurchases and dividend payments. GAAP cash flow from operations is anticipated to be between $2.4 billion and $2.9 billion for 2025.